RNS REACH
AIM: FIPP
9 May 2017
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio News
Exscientia Announces EUR250 Million Collaboration for a Multiple-Product Development and Licence Option Agreement with Sanofi
Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that its portfolio company Exscientia Limited ("Exscientia") has today announced a collaboration to develop bispecific-small-molecule drugs.
The full text of this announcement is set out below.
9 May 2017, Dundee, UK
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
Delivery of new therapies for metabolic disease (such as diabetes) is hampered by a paucity of single targets that are amenable to drug discovery. To address this challenge, Exscientia will apply its unique platform to identify and validate combinations of drug targets* that could work synergistically and be amenable to Exscientia's powerful bispecific-small-molecule design strategy - where a small molecule is designed to be compatible with two distinct drug targets.
Starting with over a thousand disease-relevant target combinations, Exscientia will triage opportunities and prioritise those with promising bispecific binding potential. Target pairs fulfilling these initial tractability criteria will pass through to Exscientia's lead-finding platform in order to generate bispecific-small-molecule compounds that can further validate the biological hypothesis. Bispecific small molecules passing all these quality gates may progress to full candidate delivery projects for Sanofi.
Rapid delivery of multiple bispecific opportunities will be empowered by a pipeline of Exscientia capabilities driven by Artificial Intelligence and enabled automated design.
As part of this agreement, Exscientia will be responsible for all compound design, whilst chemistry synthesis will be delivered by Sanofi. Further assays, preclinical experiments and subsequent trials for compounds progressing to the clinic will be managed by Sanofi, where Sanofi exercises the licence option.
The commercial terms for this agreement include the payment of research funding in order to identify those target pairs with the best combination of chemical compatibility and strong biological relevance plus further funding for prioritised candidate delivery opportunities. For compounds reaching agreed delivery criteria, a series of milestones covering both non-clinical and clinical may be payable by Sanofi. Finally, any licensed products reaching the market will qualify for recurrent sales milestones. The total amount potentially payable by Sanofi to Exscientia on achieving these milestones is EUR250 million.
Commenting on this relationship, Andrew Hopkins (CEO, Exscientia) said: "We are delighted that Sanofi is engaging with Exscientia in a comprehensive, end-to-end drug discovery project. This agreement highlights Exscientia's ability to apply bispecific drug design in a comprehensive and highly productive manner. Sanofi has put together an excellent experimental backbone for this collaboration and we look forward to delivering high-value projects for the company."
*Many effective drugs act via modulation of multiple proteins rather than single targets. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggests bispecific compounds could deliver superior clinical efficacy.
http://www.prnewswire.com/news-releases/exscientia-announces-eur250-million-collaboration-for-a-multiple-product-development-and-licence-option-agreement-with-sanofi-621706173.html
Notes for editors
Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, we are the first company to automate drug design, surpassing conventional approaches.
Our innovative platform enables breakthrough productivity gains with new approaches to improve drug efficacy. It is delivering a pipeline of efficacious, bispecific small molecules, as well as highly selective single target candidates, for multiple indications.
Each bispecific small molecule is a single compound with integrated pharmacology against two distinct targets. This offers an innovative strategy to address efficacy challenges. Exscientia has also extended its capabilities to phenotypic-driven drug discovery, where complex disease profiles are addressed.
Exscientia is developing candidate molecules through collaborations with leading biopharmaceutical companies; current partners include Evotec (immuno-oncology), Sanofi (metabolic diseases), Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals (CNS).
Media enquiries:
Mark Swindells - Chief Operating Officer [email protected]
Mark Swallow / Katja Stout - Citigate Dewe Rogerson [email protected]
+44 207 638 9571
ENDS
For further information:
Frontier IP Group Plc |
T: 0131 240 1251 |
Neil Crabb, Chief Executive Company website: www.frontierip.co.uk |
|
|
|
Cenkos Securities plc (Nominated Adviser and Joint Broker) |
T: 0131 220 6939 |
Neil McDonald / Beth McKiernan |
|
|
|
Peterhouse Corporate Finance Limited (Joint Broker) |
T: 020 7469 0935 |
Lucy Williams |
|
|
|
Kreab (Financial PR) |
T: 020 7074 1800 |
Robert Speed / Matthew Jervois |
|
Notes to Editor:
About Frontier IP Group plc
www.frontierip.co.uk.
Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses.
